NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both s

Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy rati

Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rat

Bank of America Corp DE reduced its stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) by 85.5% durin

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE

BlackRock Inc. bought a new stake in NeuroPace, Inc. (NASDAQ: NPCE) during the second quarter, accor

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuatio

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regul

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026

NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RN

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus

NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consen

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday&#39

US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earning

HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintai

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopa

NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket appr

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and inves

The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. Whil

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at